These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 21803735)

  • 21. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.
    Giafis N; Katsoulidis E; Sassano A; Tallman MS; Higgins LS; Nebreda AR; Davis RJ; Platanias LC
    Cancer Res; 2006 Jul; 66(13):6763-71. PubMed ID: 16818652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
    Bhattacharya B; Akram M; Balasubramanian I; Tam KK; Koh KX; Yee MQ; Soong R
    Cancer Biol Ther; 2012 Jan; 13(1):34-42. PubMed ID: 22336586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
    López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
    Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
    Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.
    Werzowa J; Koehrer S; Strommer S; Cejka D; Fuereder T; Zebedin E; Wacheck V
    J Invest Dermatol; 2011 Feb; 131(2):495-503. PubMed ID: 21048785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
    Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
    Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
    Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
    Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.
    Kojima K; Shimanuki M; Shikami M; Samudio IJ; Ruvolo V; Corn P; Hanaoka N; Konopleva M; Andreeff M; Nakakuma H
    Leukemia; 2008 Sep; 22(9):1728-36. PubMed ID: 18548093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
    Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
    Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway.
    Wang WZ; Pu QH; Lin XH; Liu MY; Wu LR; Wu QQ; Chen YH; Liao FF; Zhu JY; Jin XB
    Leuk Res; 2015 Oct; 39(10):1117-24. PubMed ID: 26248946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma.
    Guo S; Lopez-Marquez H; Fan KC; Choy E; Cote G; Harmon D; Nielsen GP; Yang C; Zhang C; Mankin H; Hornicek FJ; Borger DR; Duan Z
    PLoS One; 2014; 9(4):e93996. PubMed ID: 24695632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
    Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
    Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation.
    Dembitz V; Lalic H; Ostojic A; Vrhovac R; Banfic H; Visnjic D
    Int J Hematol; 2015 Jul; 102(1):12-24. PubMed ID: 25758096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.
    Segerström L; Baryawno N; Sveinbjörnsson B; Wickström M; Elfman L; Kogner P; Johnsen JI
    Int J Cancer; 2011 Dec; 129(12):2958-65. PubMed ID: 21717457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity.
    Ding Q; Gu R; Liang J; Zhang X; Chen Y
    Med Oncol; 2013 Mar; 30(1):395. PubMed ID: 23335068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells.
    Mise J; Dembitz V; Banfic H; Visnjic D
    Pathol Oncol Res; 2011 Sep; 17(3):645-56. PubMed ID: 21336564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.